The march towards CFTR modulator access for all people with CF: The end of the beginning.
作者信息
VanDevanter Donald R
机构信息
Case Western Reserve University School of Medicine, Cleveland, OH, United States.
出版信息
J Cyst Fibros. 2021 Mar;20(2):185-187. doi: 10.1016/j.jcf.2021.01.005. Epub 2021 Jan 22.
PMID:33495080
Abstract
摘要
相似文献
1
The march towards CFTR modulator access for all people with CF: The end of the beginning.让所有囊性纤维化患者都能用上CFTR调节剂的征程：初见成效。
J Cyst Fibros. 2021 Mar;20(2):185-187. doi: 10.1016/j.jcf.2021.01.005. Epub 2021 Jan 22.
2
Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in a man with A559T and 3120+1G>CFTR variants.依列卡福妥/替扎卡福妥/依伐卡托对一名携带A559T和3120+1G>CFTR变异的男性的临床疗效。
Pediatr Pulmonol. 2024 Jul;59(7):2009-2011. doi: 10.1002/ppul.26997. Epub 2024 Apr 12.
3
Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.适合调节剂药物的患者：来自土耳其囊性纤维化登记处的数据。
Pediatr Pulmonol. 2020 Sep;55(9):2302-2306. doi: 10.1002/ppul.24854. Epub 2020 May 26.
4
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.VX-445-泰泽卡托维瓦卡托联合治疗伴有一个或两个 Phe508del 等位基因的囊性纤维化患者。
N Engl J Med. 2018 Oct 25;379(17):1612-1620. doi: 10.1056/NEJMoa1807120. Epub 2018 Oct 18.
5
Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.囊性纤维化：高效靶向治疗药物的出现及其潜在的临床意义。
Am J Respir Crit Care Med. 2020 May 15;201(10):1193-1208. doi: 10.1164/rccm.201910-1943SO.
6
Cystic fibrosis transmembrane conductance regulator modulators for cystic fibrosis: a new dawn?囊性纤维化跨膜电导调节因子调节剂治疗囊性纤维化：新的曙光？
Arch Dis Child. 2021 Oct;106(10):941-945. doi: 10.1136/archdischild-2020-320680. Epub 2021 Mar 30.
7
Elexacaftor/Tezacaftor/Ivacaftor Effectiveness in N1303K Variant in Adult People With Cystic Fibrosis.依列卡福妥/替扎卡福妥/依伐卡托对成年囊性纤维化患者N1303K变异体的有效性
Arch Bronconeumol. 2024 Aug;60(8):526-528. doi: 10.1016/j.arbres.2024.04.007. Epub 2024 Apr 24.
8
Treating Specific Variants Causing Cystic Fibrosis.治疗导致囊性纤维化的特定变体。
JAMA. 2017 Dec 5;318(21):2130-2131. doi: 10.1001/jama.2017.16823.
9
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.VX-659-泰泽卡托维伐替卡与依伐卡托维在携带一个或两个 Phe508del 等位基因的囊性纤维化患者中的疗效。
N Engl J Med. 2018 Oct 25;379(17):1599-1611. doi: 10.1056/NEJMoa1807119. Epub 2018 Oct 18.
10
New Drug Hailed as Major Breakthrough in Cystic Fibrosis.新药被誉为囊性纤维化治疗的重大突破。
Am J Med Genet A. 2020 Jan;182(1):8-9. doi: 10.1002/ajmg.a.61420.
Zotero 插件